Bristol-Myers Squibb Company and Pfizer
Bristol-Myers Squibb and Pfizer Announce Plans To Submit Regulatory Filing for Apixaban In Europe
Published in Vaccine Weekly, December 30th, 2009
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced that the companies are planning to submit an application for regulatory approval of apixaban in Europe for the prevention of venous thromboembolism (VTE) after orthopedic surgery in the first half of 2010. The application will be supported by ADVANCE-2 and ADVANCE-3, two clinical trials that evaluated apixaban versus the European dosing regimen of enoxaparin for prevention of VTE in patients undergoing orthopedic surgery. Results of ADVANCE-2 were first presented in July 2009 at the 22nd Congress of the International Society on Thrombosis and Haemostasis in Boston. The ADVANCE-3 data will be submitted for publication...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2009-12-30)
More Articles from Vaccine Weekly
- Rockefeller University Press
Hindering HIV-1-fighting immune cells - Thomas Jefferson University
Research reveals further progress toward AIDS vaccine - Adenovirus
Reports summarize adenovirus research from Vrije University Amsterdam - Candidiasis
New candidiasis data have been reported by researchers at University of Sao Paulo - Immunization
Research from University of Alabama provide new insights into immunization - Life Sciences
Data on life sciences published by researchers at Ernst-Moritz-Arndt University - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
